摘要
目的采用重组人血管内皮抑制素(恩度)联合经典化疗方案治疗临床分期Ⅲ期以上的恶性肿瘤,观察用药后的疗效及毒副作用。方法经过病理组织切片检查确诊为恶性肿瘤的患者117例,采用恩度联合无交叉耐药的化疗药物方案治疗,联合用药2周期后评价疗效与不良反应,评估患者治疗开始到无疾病进展时间的生活质量。结果 117例患者在完成联合治疗后按照有关标准进行有效性与安全性评价,其中完全缓解12例,部分缓解30例,疾病稳定58例,疾病进展17例;客观有效率为35.8%,疾病控制率为85.4%。结论晚期恶性肿瘤患者低下的生活质量得以改善和稳定,且恩度联合化疗使用的毒性低,值得临床上推广应用,但远期疗效仍需进一步观察。
Objective To observe the efficacy and adverse effects after applying recombinant human endostatin （Endostar） combined with classical chemotherapy to malignant tumors of more than clinical stage phase 111. Methods 117 patients diagnosed as malignant tumors after histopathological examination, underwent Endostar combined chemotherapy with no cross-resistance. Two cycles after the combined therapy, the efficacy and adverse reactions were evaluated. Results The efficacy and safety were evaluated in accordance with the relevant standards after the combination therapy including 12 cases of CR, 30 cases of PR, 58 cases of SD,disease PD 17;RR was 35.8% , DCR was 85.4%. Conclusion The Endostar combined chemotherapy can improve the life quality of the patients with malignances, and lower toxicity, which is worthy of clinical application, but the long-term efficacy remains to be seen.
出处
《安徽医科大学学报》
CAS
北大核心
2012年第10期1209-1211,共3页
Acta Universitatis Medicinalis Anhui
基金
中华国际医学会基金资助(编号:CIMF-F-H001-001)
先声药业公司基金资助(编号:Endo-028)
关键词
重组人血管内皮抑制素
晚期恶性肿瘤
靶向治疗
化疗
recombinant human endostatin advanced malignancies targeted therapy chemotherapy
